Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T...

Reported positive initial data from Phase 1 heme program at the 65 th American Society of Hematology (ASH) Annual Meeting Clearance of INDs for four TCR-Ts, including a TCR-T for PRAME, in support of use of multiple TCRs in combination for the solid tumor clinical trial Entered a collaboration with...